title: Immunoactivating potential of multilamellar liposome vesicles (MLV) in murine popliteal lymph node (PLN) test.
abstract: Immunoactivating properties of subcutaneously injected small unilamellar vesicles (SUV) and multilamellar liposome vesicles (MLV) were studied in relation to different transition temperatures (Tc) of phospholipids. Liposome-induced proliferative reaction in the popliteal lymph node (PLN) was quantified by subsequent cytometric assay. Early cell activation during the onset of PLN reaction was monitored by immunophenotyping of lymphocyte subsets stained with a panel of monoclonal antibodies (mAbs) and gating the subset-specific large/activated cells. Injection of MLV liposomes containing distearoyl phosphatidylcholine (DSPC) and dipalmityl phosphatidylcholine (DPPC), characterized by relatively high Tc, resulted in a marked PLN reaction, increased numbers of CD4+, CD8+, Ig+ subsets and increased proportions of large/activated EAM+ (CD69+) and CD25+ (IL-2 receptor+) cells. The reaction was dose and time dependent. In contrast, injection of MLV liposomes containing lipids of low Tc, such as egg phosphatidylcholine (egg PC) and dimyristoyl phosphatidylcholine (DMPC), did not show any immunoactivation. In addition, there was a highly reduced immunoactivating potential of small-size SUV liposomes over large-sized MLV of identical phospholipid composition. Generally, both lipid composition and vesicle size appeared to be essential for the immunoactivating potential of liposomes. The data suggest a possible correlation between the Tc of the phospholipid and the immunoactivating potential of the large-sized MLV liposomes.
authors.affiliation: Département des Sciences Biologiques, Université du Québec à Montréal, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Desjardins
authors.forename: K
authors.initials: K
authors.lastname: Krzystyniak
authors.forename: H M
authors.initials: HM
authors.lastname: Thérien
authors.forename: W
authors.initials: W
authors.lastname: Banska
authors.forename: P
authors.initials: P
authors.lastname: Tancrede
authors.forename: M
authors.initials: M
authors.lastname: Fournier
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007136:Immunoglobulins / Q000276:immunology; D016130:Immunophenotyping; D007279:Injections, Subcutaneous; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology*; D008198:Lymph Nodes / Q000166:cytology / Q000276:immunology*; D008213:Lymphocyte Activation / Q000187:drug effects; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D009929:Organ Size; D010743:Phospholipids / Q000737:chemistry / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D007136:Immunoglobulins; D008081:Liposomes; D010743:Phospholipids